ABT-578

Known as: ABT 578, ABT578 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2006
024620022006

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2006
Review
2006
Drug-eluting stents have been shown to reduce the rate of restenosis significantly in all types of lesion, patient and clinical… (More)
Is this relevant?
2005
2005
Stent-based delivery of the antiproliferative and immunosuppressive macrocyclic lactone sirolimus reduces neointimal formation… (More)
Is this relevant?
2005
2005
We report here a specific, automated LC/LC-MS/MS assay for the quantification of ABT-578 in human and rabbit blood and rabbit… (More)
Is this relevant?
2005
2005
ABT-578, a sirolimus analog, is being developed for administration from drug-eluting stents to prevent postimplantation… (More)
Is this relevant?
2005
2005
OBJECTIVE ABT-578, a tetrazole analogue of sirolimus (rapamycin), possesses anti-restenosis activity. The aim of this study was… (More)
Is this relevant?
2004
2004
ABT-578 is a new synthetic analog of rapamycin, designed to inhibit smooth muscle cell proliferation—a key contributor to… (More)
  • figure 1
  • figure 2
Is this relevant?
2004
2004
We report here a quantitative method for the analysis of ABT-578 in human whole blood samples. Sample preparation was achieved by… (More)
Is this relevant?
Review
2004
Review
2004
ABT-578 is a new synthetic analog of rapamycin, designed to inhibit smooth muscle cell proliferation-a key contributor to… (More)
Is this relevant?
2004
2004
Quantitative determination of drug concentrations in tissue samples can provide critical information for drug metabolism… (More)
Is this relevant?
2004
2004
The efficacy and safety of drug-eluting coronary stents might differ depending on the pharmacologic agents and stent delivery… (More)
Is this relevant?